LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SILO
Silo Pharma, Inc.
There isn't enough reported data to score SILO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SILO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SILO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | โ |
| Current | 46x | $1,427 | โ |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SILO PE Valuation
SILO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SILO Forward outlook
There aren't enough analyst estimates for SILO to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus SILO down 177%.
SILO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$13.80 | +$4.07 |
| Q2 2025 | -$15.30 | +$2.42 |
| Q1 2025 | -$17.10 | +$0.77 |
| Q4 2024 | -$17.85 | +$0.17 |
| Q3 2024 | -$17.87 | +$12.45 |
| Q2 2024 | -$17.72 | +$16.80 |
| Q1 2024 | -$17.87 | +$19.35 |
| Q4 2023 | -$18.02 | +$14.85 |
SILO is still losing money, but far less than before: $13.80 per share over the past year, against $52.50 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SILO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SILO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $18K | 0% |
| Q4 2025 | $18K | 0% |
| Q3 2025 | $18K | 0% |
| Q2 2025 | $18K | 0% |
| Q1 2025 | $18K | 0% |
| Q4 2024 | $18K | 0% |
| Q3 2024 | $18K | 0% |
| Q2 2024 | $18K | 0% |
SILO's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -8846% | -2777 points |
| Q4 2025 | -4363% | +5696 points |
| Q3 2025 | -6388% | -785 points |
| Q2 2025 | -6927% | -1364 points |
| Q1 2025 | -6070% | -1191 points |
| Q4 2024 | -10060% | -3604 points |
| Q3 2024 | -5604% | -1313 points |
| Q2 2024 | -5563% | +623 points |
SILO's operating margin was โ8846% last quarter, down 2777 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SILO on cash generation, producing positive trailing cash flow while its opponent burns cash.
SILO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$781.9K | +$503.4K |
| Q1 2026 | -$822.6K | +$817.7K |
| Q4 2025 | -$780.3K | +$137.2K |
| Q3 2025 | -$955.5K | +$391K |
| Q2 2025 | -$1.3M | -$553.5K |
| Q1 2025 | -$1.6M | -$802.1K |
| Q4 2024 | -$917.4K | -$7.4K |
| Q3 2024 | -$1.3M | -$274.7K |
SILO has burned cash in almost every quarter: โ$3M over the past year, against โ$5M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SILO Net Leverage
SILO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SILO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 12.9 | Oversold |
SILO's weekly RSI is 35 (neutral) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SILO PE vs Healthcare Sector
| Metric | SILO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
SILO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SILO on trend strength, trading above more of its moving averages.
SILO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 33% above |
| 20 week MA | $2.77 | 31% below |
| 50 week MA | $4.58 | 58% below |
| 100 week MA | $8.91 | 79% below |
| 200 week MA | $17.4 | 89% below |
SILO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 89% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SILO on returns for 2026, with the stronger performance.
SILO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $262.5 | $101.3 | -61% |
| 2022 | $101.3 | $45.0 | -56% |
| 2023 | $45.0 | $21.6 | -52% |
| 2024 | $21.6 | $14.1 | -35% |
| 2025 | $14.1 | $5.47 | -61% |
| 2026 YTD | $5.47 | $1.91 | -65% |
SILO has finished every year since 2021 lower, and it's down 65% so far in 2026.